ArticleFrontiers in immunology2026
Recurrent spinal IgG4-related hypertrophic pachymeningitis and its management: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: In this report, we share a case of recurrent spinal immunoglobulin G4 (IgG4)-related hypertrophic pachymeningitis (IgG4-RHP) in a patient who initially achieved near-complete recovery of muscle weakness after decompression surgery and steroid therapy. However, the patient experienced disease recurrence after discontinuing steroid therapy due to intolerable side effects. Materials and methods: We reviewed the patient's medical records, including the pathology images and report certified by the pathologist. After disease recurrence, the patient was treated with oral prednisolone 5 mg twice daily and oral azathioprine 50 mg daily initially, which was then increased to 75 mg daily a month later. Results: After 6 months of combined therapy with prednisolone and azathioprine, there was significant improvement in the patient's clinical symptoms. Interval MRI scans showed resolution of the lesion, and the serum IgG4 concentration also returned to the normal range. Conclusion: Although the pachymeninges (dura mater) are rarely involved in IgG4-related disease, it should be considered in the differential diagnosis of long-segment, homogeneously enhanced epidural masses. Steroid therapy is the first-line therapy for IgG4-RHP, while steroid-sparing agents should be added in refractory or recurrent cases. Surgical decompression is necessary in cases of acute neurological deterioration. A combination of a steroid and an immunomodulatory agent may be considered in cases of recurrent disease. More importantly, we demonstrated details of the clinical course of IgG4-RHP and the treatment effects of both surgical decompression of the spinal cord and medical treatment with steroids in combination with an immunomodulator (azathioprine), particularly in the setting of disease recurrence. This was done in full detail with interval imaging scans showing the response to treatment, along with serial tracking of the antibody levels, which, to our knowledge, had not been reported prior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.